Plasma apoCIII Levels in Relation to Inflammatory Traits and Metabolic Syndrome in Patients not Treated with Lipid-lowering Drugs Undergoing Coronary Angiography.

Na Qiong WU; Sha LI; Yan Zhang; Cheng Gang Zhu; Yuan Lin Guo; Ying Gao; Ping Qing; Jing Sun; Geng Liu; Qian Dong; Jian Jun LI

Return

Plasma apoCIII Levels in Relation to Inflammatory Traits and Metabolic Syndrome in Patients not Treated with Lipid-lowering Drugs Undergoing Coronary Angiography.

Author: Na Qiong WU ¹ ; Sha LI ¹ ; Yan ZHANG ¹ ; Cheng Gang ZHU ¹ ; Yuan Lin GUO ¹ ; Ying GAO ¹ ; Ping QING ¹ ; Jing SUN ¹ ; Geng LIU ¹ ; Qian DONG ¹ ; Jian Jun LI ¹
Author Information

1. Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China.
Publication Type:Journal Article
Keywords: Apolipoprotein CIII; Inflammation; Metabolic syndrome
MeSH: Adult; Aged; Apolipoprotein C-III; blood; Biomarkers; blood; C-Reactive Protein; metabolism; Coronary Angiography; Cross-Sectional Studies; Female; Humans; Inflammation; blood; Leukocyte Count; Male; Metabolic Syndrome; blood; Middle Aged
From: Biomedical and Environmental Sciences 2017;30(1):1-9
CountryChina
Language:English
Abstract:
OBJECTIVEAssessment of the comprehensive relationship among apolipoprotein CIII (apoCIII) levels, inflammation, and metabolic disorders is rare.
METHODSA total of 1455 consecutive patients not treated with lipid-lowering drugs and undergoing coronary angiography were enrolled in this cross-sectional study. A mediation analysis was used to detect the underlying role of apoCIII in the association of inflammation with metabolic syndrome (MetS).
RESULTSPatients with MetS showed higher levels of apoCIII [95.1 (73.1-131.4) vs. 81.7 (58.6-112.4) μg/mL, P < 0.001] and inflammatory markers [high sensitivity C-reactive protein, 1.7 (0.8-3.4) vs. 1.1 (0.5-2.2) mg/L; white blood cell count, (6.48 ± 1.68) vs. (6.11 ± 1.67) × 109/L]. The levels of apoCIII and inflammatory markers increased with the number of metabolic risk components (all P < 0.001). Furthermore, apoCIII levels were associated with virtually all individual MetS risk factors and inflammatory markers (all P < 0.05). Importantly, the prevalence of MetS in each metabolic disorder rose as apoCIII levels increased (all P < 0.05). Mediation analysis showed that apoCIII partially mediated the effect of inflammation on MetS independently from triglycerides.
CONCLUSIONPlasma apoCIII levels were significantly associated with the development and severity of MetS, and a role of apoCIII in the effect of inflammation on the development of MetS was identified.